BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: A review. World J Hepatol 2013; 5(12): 666-675 [PMID: 24409335 DOI: 10.4254/wjh.v5.i12.666] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Muhammad H, Tehreem A, Hammami MB, Ting PS, Idilman R, Gurakar A. Hepatitis D virus and liver transplantation: Indications and outcomes. World J Hepatol 2021; 13(3): 291-299 [PMID: 33815673 DOI: 10.4254/wjh.v13.i3.291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Jang TY, Wei YJ, Yeh ML, Liu SF, Hsu CT, Hsu PY, Liu TW, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. J Formos Med Assoc 2021;120:303-10. [PMID: 33109431 DOI: 10.1016/j.jfma.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Chen M, Du D, Zheng W, Liao M, Zhang L, Liang G, Gong M. Small hepatitis delta antigen selectively binds to target mRNA in hepatic cells: a potential mechanism by which hepatitis D virus downregulates glutathione S-transferase P1 and induces liver injury and hepatocarcinogenesis. Biochem Cell Biol. 2019;97:130-139. [PMID: 30153423 DOI: 10.1139/bcb-2017-0321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Bahcecioglu IH, Sahin A. Treatment of Delta Hepatitis: Today and in the Future - A review. Infectious Diseases 2017;49:241-50. [DOI: 10.1080/23744235.2016.1271998] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
5 Maslennikov R, Ivashkin V, Efremova I, Shirokova E. Immune disorders and rheumatologic manifestations of viral hepatitis. World J Gastroenterol 2021; 27(18): 2073-2089 [PMID: 34025065 DOI: 10.3748/wjg.v27.i18.2073] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 McAfee MS, Huynh TP, Johnson JL, Jacobs BL, Blattman JN. Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity. Virology 2015;484:153-62. [PMID: 26099694 DOI: 10.1016/j.virol.2015.05.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Coppola N, Alessio L, Onorato L, Sagnelli C, Sagnelli E, Pisaturo M. HDV infection in immigrant populations. J Med Virol 2019;91:2049-58. [PMID: 31429940 DOI: 10.1002/jmv.25570] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Mentha N, Clément S, Negro F, Alfaiate D. A review on hepatitis D: From virology to new therapies. J Adv Res 2019;17:3-15. [PMID: 31193285 DOI: 10.1016/j.jare.2019.03.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
9 Ye X, Tateno C, Thi EP, Kakuni M, Snead NM, Ishida Y, Barnard TR, Sofia MJ, Shimada T, Lee ACH. Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model. ACS Infect Dis 2019;5:738-49. [PMID: 30408957 DOI: 10.1021/acsinfecdis.8b00192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
10 Abbas Z, Abbas M. Management of hepatitis delta: Need for novel therapeutic options. World J Gastroenterol 2015; 21(32): 9461-9465 [PMID: 26327754 DOI: 10.3748/wjg.v21.i32.9461] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Faria LC, Terrabuio DRB, Leblebicioglu H, Huprikar S. Viral Hepatitis Recommendations for Solid-Organ Transplant Recipients and Donors. Transplantation 2018;102:S66-71. [PMID: 29381580 DOI: 10.1097/TP.0000000000002013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Xue MM, Glenn JS, Leung DH. Hepatitis D in Children. Journal of Pediatric Gastroenterology & Nutrition 2015;61:271-81. [DOI: 10.1097/mpg.0000000000000859] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
13 Monette A, Mouland AJ. T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders. Int Rev Cell Mol Biol 2019;342:175-263. [PMID: 30635091 DOI: 10.1016/bs.ircmb.2018.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Landahl J, Bockmann JH, Scheurich C, Ackermann C, Matzat V, Heide J, Nuurei T, D'Antonio G, von Felden J, Sette A, Peine S, Lohse AW, Luetgehetmann M, Marget M, Sidney J, Schulze Zur Wiesch J. Detection of a Broad Range of Low-Level Major Histocompatibility Complex Class II-Restricted, Hepatitis Delta Virus (HDV)-Specific T-Cell Responses Regardless of Clinical Status. J Infect Dis 2019;219:568-77. [PMID: 30247653 DOI: 10.1093/infdis/jiy549] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf) 2019;7:231-45. [PMID: 32477569 DOI: 10.1093/gastro/goz023] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Giersch K, Dandri M. Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte. J Clin Transl Hepatol. 2015;3:220-229. [PMID: 26623269 DOI: 10.14218/jcth.2015.00018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
17 Dey D, Banerjee M. Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol 2016;4:248-57. [PMID: 27777893 DOI: 10.14218/JCTH.2016.00025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Yan NN, Xu YC, Zhang FC. Circular RNAs and tumors. Shijie Huaren Xiaohua Zazhi 2015; 23(35): 5670-5676 [DOI: 10.11569/wcjd.v23.i35.5670] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Koh C, Heller T, Glenn JS. Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology. 2019;156:461-476.e1. [PMID: 30342879 DOI: 10.1053/j.gastro.2018.09.058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
20 Sharma N, Singh SK. Implications of non-coding RNAs in viral infections. Rev Med Virol 2016;26:356-68. [PMID: 27401792 DOI: 10.1002/rmv.1893] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
21 Guo Z, King T. Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection. Int J Mol Sci 2015;16:19537-52. [PMID: 26295228 DOI: 10.3390/ijms160819537] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Colagrossi L, Salpini R, Scutari R, Carioti L, Battisti A, Piermatteo L, Bertoli A, Fabeni L, Minichini C, Trimoulet P, Fleury H, Nebuloso E, De Cristofaro M, Cappiello G, Spanò A, Malagnino V, Mari T, Barlattani A, Iapadre N, Lichtner M, Mastroianni C, Lenci I, Pasquazzi C, De Sanctis GM, Galeota Lanza A, Stanzione M, Stornaiuolo G, Marignani M, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Perno CF, Coppola N, Svicher V. HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. Viruses 2018;10:E363. [PMID: 29987240 DOI: 10.3390/v10070363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Abbas M, Abbas Z. Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D. World J Hepatol 2017; 9(22): 967-972 [PMID: 28839517 DOI: 10.4254/wjh.v9.i22.967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, Sun W, Dou K, Li H. Circular RNA: A new star of noncoding RNAs. Cancer Lett. 2015;365:141-148. [PMID: 26052092 DOI: 10.1016/j.canlet.2015.06.003] [Cited by in Crossref: 798] [Cited by in F6Publishing: 848] [Article Influence: 114.0] [Reference Citation Analysis]
25 Shirvani-Dastgerdi E, Amini-Bavil-Olyaee S, Alavian SM, Trautwein C, Tacke F. Comprehensive analysis of mutations in the hepatitis delta virus genome based on full-length sequencing in a nationwide cohort study and evolutionary pattern during disease progression. Clin Microbiol Infect. 2015;21:510.e11-510.e23. [PMID: 25656625 DOI: 10.1016/j.cmi.2014.12.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
26 Belyhun Y, Liebert UG, Maier M. Clade homogeneity and low rate of delta virus despite hyperendemicity of hepatitis B virus in Ethiopia. Virol J 2017;14:176. [PMID: 28899424 DOI: 10.1186/s12985-017-0844-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. 2014;20:1829-1842. [PMID: 25404635 DOI: 10.1261/rna.047126.114] [Cited by in Crossref: 633] [Cited by in F6Publishing: 614] [Article Influence: 90.4] [Reference Citation Analysis]
28 Fatehi Chenar F, Kyrychko YN, Blyuss KB. Mathematical model of immune response to hepatitis B. J Theor Biol 2018;447:98-110. [PMID: 29574141 DOI: 10.1016/j.jtbi.2018.03.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]